Reference

Frequency of acute adverse events to a non-ionic low-osmolar contrast medium: the effect of verbal interview

Frequency of acute adverse events to a non-ionic low-osmolar contrast medium: the effect of verbal interview. Thomsen, Henrik S. (MRI-Unit, Department of Diagnostic Radiology 54E2, Herlev Hospital, University of Copenhagen, Herlev DK-2730, Den.). Pharmacology & Toxicology (Copenhagen), 80(2), 108-110 (English) 1997 Munksgaard. CODEN: PHTOEH.In this study，131410-48-5 is also used. ISSN: 0901-9928. DOCUMENT TYPE: Journal CA Section: 8 (Radiation Biochemistry) The effect of a standardized verbal interview on the frequency of reported adverse events to an i.v. injection of a non-ionic low-osmolar magnetic resonance (MR) contrast medium was studied during a low noise (low anxiety) magnetic resonance imaging (MRI) examn. During a 26-mo period 863 patients had an i.v. bolus (<10 s.) injection of either 0.1 mmol/kg b.wt. or 0.3 mmol/kg b.wt. gadodiamide, were examd. in 0.1 T MRI unit. All patients received written information about the examn., but no specific information about possible adverse events to the contrast medium. During the first 15 mo, 479 patients were asked after the examn. by the same radiographer the following question "Did you feel anything in relation to or after the contrast medium injection". If the answer was affirmative, the patient was asked to specify the experience. During the subsequent 11-mo period, 384 patients had no interview about whether they felt anything in relation to the contrast medium injection. Only 9 out of 863 patients reported an adverse event and they all belonged to the group, which was interviewed. In 8 cases the adverse events lasted less than 5 min. The ninth patient had an attack of migraine 20 min. after the injection of the contrast medium. In one of the patients, who experienced nausea, it was necessary to postpone scanning for 2 min. Two of the 9 adverse events were considered to be unrelated to the contrast medium. None of the 121 patients receiving the triple dose reported an adverse event. The frequency of reported adverse events depends on whether this information is obtained by active questioning. All reported adverse events were clin. mild and no dose-response effect was obsd. .

Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier

Neurotoxicity of gadolinium contrast agents for magnetic resonance imaging in rats with osmotically disrupted blood-brain barrier. Takahashi, Masaya; Tsutsui, Hirokazu; Murayama, Chie; Miyazawa, Tomoaki; Fritz-Zieroth, Bernhard (Research Department, Yodogawa 532, Japan). Magnetic Resonance Imaging, 14(6), 619-623 (English) 1996 Elsevier. CODEN: MRIMDQ. ISSN: 0730-725X. DOCUMENT TYPE: Journal CA Section: 8 (Radiation Biochemistry) The neurotoxicity of i.v. injected Gadolinium (Gd) complexes to rats with disrupted blood-brain barrier (BBB) was evaluated. After disruption of the BBB by infusion of mannitol soln., one of several contrast agents tested was injected i.v. at a dose of 1 or 3 mmol Gd/kg, and neurol. symptoms were graded. The concns. of Gd in brain and plasma were also measured. Injection of Gd-DTPA at a dose of 3 mmol Gd/kg did not change behavior. On the other hand, Gd-DTPA-BMA, Gd-DO3A-butrol, and Gd-DO3A-HP each induced behavioral impairments, and some animals died within 1 h after injection. Gd-DO3A-HP showed lethal effect even at a dose of 1 mmol/kg. The concn. of Gd in the brain of the animals injected with Gd-DO3A-HP at 3 mmol Gd/kg was essentially the same as that of animals injected with Gd-DTPA at the same dose. 138071-82-6 and 131410-48-5 are just another two chemicals used in this study. The neurotoxicity of the contrast agents tested was graded as follows: Gd-DTPA ￡ Gd-DTPA-BMA = Gd-DO3A-butrol < Gd-DO3A-HP. .